

External beam radiation therapy versus stent insertion for dysphagia relief in esophageal cancer: a multi-center randomized trial

Published: 14-11-2018

Last updated: 11-04-2024

Primary objectiveThe primary objective of this study is to compare the efficacy of EBRT versus SEMS insertion for palliation of malignant dysphagia in esophageal cancer patients at 4 weeks after start of treatment.**Secondary objectives**Secondary...

| | |
|------------------------------|--|
| Ethical review | Approved WMO |
| Status | Recruitment stopped |
| Health condition type | Malignant and unspecified neoplasms gastrointestinal NEC |
| Study type | Interventional |

Summary

ID

NL-OMON48565

Source

ToetsingOnline

Brief title

EXTENT trial

Condition

- Malignant and unspecified neoplasms gastrointestinal NEC
- Gastrointestinal neoplasms malignant and unspecified
- Gastrointestinal therapeutic procedures

Synonym

difficulty swallowing due to esophageal cancer, Dysphagia due to esophageal cancer

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Dysphagia, Esophageal neoplasms, External beam radiation therapy, Self expandable metallic stents

Outcome measures

Primary outcome

Primary outcome of this study will be *dysphagia response*, regarded as *1 grade reduction of the Dysphagia Scoring Scale (DSS). Assessment of primary outcome will be conducted at 4-weeks follow-up.

Secondary outcome

Secondary study endpoints include:

- Dysphagia response over time
- Pain intensity
- Major and minor complication rate
- Quality of Life
- Costs
- Dysphagia free survival and overall survival

Study description

Background summary

The incidence of esophageal carcinoma is rapidly increasing, affecting 455,800 patients worldwide in 2012. At time of diagnosis more than half of patients have incurable disease due to metastases or poor medical condition. Dysphagia is the most common symptom of incurable obstructive esophageal cancer.

Palliative treatment aims to relieve dysphagia, maintain nutritional intake and improve quality of life. As it has been demonstrated that brachytherapy has a superior effect over stent insertion for long-term dysphagia relief, current clinical guidelines advise to use brachytherapy over self-expandable metallic stent (SEMS) insertion for dysphagia relief in patients with a life expectancy greater than 3 months. Nevertheless, previous reports show that the use of brachytherapy in current clinical practice is low and that initial palliative treatment varies with hospital of diagnosis. A recent report on the use of brachytherapy in Italian radiotherapy centers showed that in 7 out of 40 responding centers brachytherapy was used, and only 3 centers considered brachytherapy for initial treatment. This is in accordance to an earlier remark in the ESGE guidelines; the authors stated that the main limitations of brachytherapy include limited availability, technical difficulty, and need for dedicated logistics and expertise.

Alternative treatment with external beam radiation therapy (EBRT) is given for dysphagia relief in esophageal cancer. Both EBRT and SEMS insertion have proved to be effective in palliation of dysphagia symptoms, however, no comparative data about these two different modalities are available. Since we can consider both treatment modalities mainstay in the treatment of malignant dysphagia, comparative data are warranted. Therefore, we propose a study that compares the efficacy of EBRT versus SEMS insertion, for dysphagia relief in patients with esophageal cancer. Results of this study could help to further tailor palliative treatment of patients with esophageal cancer.

Study objective

Primary objective

The primary objective of this study is to compare the efficacy of EBRT versus SEMS insertion for palliation of malignant dysphagia in esophageal cancer patients at 4 weeks after start of treatment.

Secondary objectives

Secondary objectives of this study include:

- To compare DSS-response over time of EBRT versus SEMS insertion
- To compare NRS pain score of EBRT versus SEMS insertion
- To compare major and minor complication rate of EBRT versus SEMS insertion
- To compare quality of life of EBRT versus SEMS insertion
- To compare costs of EBRT versus SEMS insertion
- To compare dysphagia free survival and overall survival of EBRT versus SEMS insertion

Study design

We propose a multi-center randomized trial in the Netherlands. When patients are eligible for inclusion, patients will be randomized to either treatment arm

after informed consent is acquired. The allocation is not blinded to the patient or outcome assessor.

Intervention

Patients will be randomized to either EBRT (5 fractions of 4 Gy each with opposing fields in anterior-posterior direction) or SEMS insertion (partially covered Niti-S S Esophageal Stent).

Study burden and risks

The proposed comparative study will provide data on treatment modalities that we consider mainstay in current clinical practice. Hence, results of this study could provide information to support future studies or guidelines, ultimately, leading to an improvement of the quality of palliative care in patients with esophageal cancer. Considering both treatment modalities are available for standard care, the risk of injury as well as the potential benefits for patients participating in this trial are equal to the risk in patients who are not enrolled. A potential burden of participation could be the demand to complete a diary and several questionnaires. This will not lead to a significant risk of injury.

Blood samples will be obtained at baseline before onset of treatment. Permission for the collection of additional blood samples will be obtained separately. Hence, participants that refuse to undergo additional blood sampling can still participate in the EXTENT trial.

Contacts

Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

Doctor Molewaterplein 40
Rotterdam 3015 GD
NL

Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

Doctor Molewaterplein 40
Rotterdam 3015 GD
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Histologically proven esophageal cancer

Patients with metastases or inoperable patients

No curative treatment options available

Dysphagia grade of * 2

Age * 18 years

Written informed consent

Exclusion criteria

Malignant extrinsic compression

Previous stent placement

Evidence of tumor within 2 cm of the upper esophageal sphincter

Presence of an esophagotracheal and/or -bronchial fistula

Study design

Design

| | |
|---------------------|-------------------------|
| Study type: | Interventional |
| Intervention model: | Parallel |
| Masking: | Open (masking not used) |
| Control: | Uncontrolled |

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 03-05-2019

Enrollment: 220

Type: Actual

Medical products/devices used

Generic name: Self expandable metallic stent (partially covered Niti-S S Esophageal Stent)

Registration: Yes - CE intended use

Ethics review

Approved WMO

Date: 14-11-2018

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Approved WMO

Date: 25-06-2019

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL66604.078.18